Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2010 2
2012 1
2013 5
2014 3
2016 3
2017 3
2018 3
2019 2
2020 6
2021 14
2022 10
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M, Chia WN, Chen MI, Wang LF, Ooi EE, Kalimuddin S, Tambyah PA, Low JG, Tan YJ, Bertoletti A. Le Bert N, et al. Among authors: tan at. Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15. Nature. 2020. PMID: 32668444
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.
Meng F, Zhao J, Tan AT, Hu W, Wang SY, Jin J, Wu J, Li Y, Shi L, Fu JL, Yu S, Shen Y, Liu L, Luan J, Shi M, Xie Y, Zhou CB, Wong RW, Lu-En W, Koh S, Bertoletti A, Wang T, Zhang JY, Wang FS. Meng F, et al. Hepatol Int. 2021 Dec;15(6):1402-1412. doi: 10.1007/s12072-021-10250-2. Epub 2021 Nov 30. Hepatol Int. 2021. PMID: 34850325 Free PMC article. Clinical Trial.
SARS-CoV-2-specific T cells in infection and vaccination.
Bertoletti A, Le Bert N, Qui M, Tan AT. Bertoletti A, et al. Among authors: tan at. Cell Mol Immunol. 2021 Oct;18(10):2307-2312. doi: 10.1038/s41423-021-00743-3. Epub 2021 Sep 1. Cell Mol Immunol. 2021. PMID: 34471260 Free PMC article. Review.
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.
Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, Pade C, Gibbons JM, Le Bert N, Tan AT, Jeffery-Smith A, Tan CCS, Tham CYL, Kucykowicz S, Aidoo-Micah G, Rosenheim J, Davies J, Johnson M, Jensen MP, Joy G, McCoy LE, Valdes AM, Chain BM, Goldblatt D, Altmann DM, Boyton RJ, Manisty C, Treibel TA, Moon JC; COVIDsortium Investigators; van Dorp L, Balloux F, McKnight Á, Noursadeghi M, Bertoletti A, Maini MK. Swadling L, et al. Among authors: tan at. Nature. 2022 Jan;601(7891):110-117. doi: 10.1038/s41586-021-04186-8. Epub 2021 Nov 10. Nature. 2022. PMID: 34758478 Free PMC article.
T-cell therapy for chronic viral hepatitis.
Bertoletti A, Tan AT, Koh S. Bertoletti A, et al. Cytotherapy. 2017 Nov;19(11):1317-1324. doi: 10.1016/j.jcyt.2017.07.011. Epub 2017 Aug 25. Cytotherapy. 2017. PMID: 28847469 Review.
HBV as a target for CAR or TCR-T cell therapy.
Bertoletti A, Tan AT. Bertoletti A, et al. Curr Opin Immunol. 2020 Oct;66:35-41. doi: 10.1016/j.coi.2020.04.003. Epub 2020 Apr 30. Curr Opin Immunol. 2020. PMID: 32361634 Review.
55 results